Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Non-Current Debt (2019 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed Non-Current Debt for 7 consecutive years, with $143.7 million as the latest value for Q4 2025.

  • Quarterly Non-Current Debt fell 11.87% to $143.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $143.7 million through Dec 2025, down 11.87% year-over-year, with the annual reading at $143.7 million for FY2025, 11.87% down from the prior year.
  • Non-Current Debt hit $143.7 million in Q4 2025 for Harmony Biosciences Holdings, down from $148.5 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $195.6 million in Q2 2021 to a low of $143.7 million in Q4 2025.
  • Historically, Non-Current Debt has averaged $176.8 million across 5 years, with a median of $181.3 million in 2023.
  • Biggest five-year swings in Non-Current Debt: fell 0.18% in 2022 and later dropped 11.87% in 2025.
  • Year by year, Non-Current Debt stood at $190.0 million in 2021, then fell by 0.18% to $189.6 million in 2022, then dropped by 5.84% to $178.6 million in 2023, then decreased by 8.71% to $163.0 million in 2024, then dropped by 11.87% to $143.7 million in 2025.
  • Business Quant data shows Non-Current Debt for HRMY at $143.7 million in Q4 2025, $148.5 million in Q3 2025, and $153.3 million in Q2 2025.